While gefitinib and erlotinib are initially effective in the majority of NSCLC patients with common EGFR mutations (exon 19 deletions and L858R point mutations), acquisition of resistance invariably occurs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.